Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220033 · ClinicalTrials.gov registry record · NA
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
A NA study of Ovarian Cancer and Endometrial Cancer, sponsored by Rutgers, The State University of New Jersey.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05220033: Active NA study of Ovarian Cancer and Endometrial Cancer, sponsored by Rutgers, The State University of New Jersey.
NCT05220033 is a NA study of Ovarian Cancer and Endometrial Cancer that is active but no longer recruiting, run by Rutgers, The State University of New Jersey. The registered enrollment target is 30 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05220033, a NA study of Ovarian Cancer and Endometrial Cancer, is active but no longer recruiting, sponsored by Rutgers, The State University of New Jersey.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study looks at how well the Journey Ahead intervention works in improving coping and communication skills in participants with gynecologic cancers.
Primary Outcome
Depressive symptoms will be measures with the Beck Depression inventory which is a 21-item scale which has been widely used in studies incorporating cognitive-behavioral interventions. Calculate score bye summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
Conditions Studied
Interventions
- OTHER survey administration
- OTHER Informational intervention
Study Locations (1)
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
What the registry record for NCT05220033 still lists
NCT05220033 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower).
The record links to 6 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which survey administration is the first listed.
NCT05220033 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05220033 about?
NCT05220033 is a clinical study titled "Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer". This study looks at how well the Journey Ahead intervention works in improving coping and communication skills in participants with gynecologic cancers.
What is the current status of trial NCT05220033?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2020-07-14. Estimated completion is 2026-12-01.
What conditions does trial NCT05220033 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer, Gynecologic Cancer.
What interventions are being tested in trial NCT05220033?
The interventions under investigation include: survey administration (OTHER), Informational intervention (OTHER).
Who is sponsoring clinical trial NCT05220033?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05220033 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05220033's enrollment target sits among peer trials
30 252nd of 322 higher than 62 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
RECRUITING · NA
-
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
RECRUITING · NA
-
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI